Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
13 pending office actions • 5 art units • 11 examiners • 0 of 13 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Insilico Medicine Ip Limited currently oversees 13 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 11 distinct examiners, indicating a high level of individual scrutiny for the portfolio. The prosecution activity is spread through 5 distinct art units, which reflects a range of technical applications within the biotechnology and pharmaceutical sectors.
WILLIS, DOUGLAS M is identified as the busiest examiner, managing 2 pending office actions. This concentration of actions is higher than that of the other distinct examiners in the portfolio, as the remaining pending actions are split among the other examiners. The ratio of 13 actions to 11 examiners suggests that most examiners are handling an individual matter for the company.
The presence of 5 distinct art units alongside the pending office actions shows that the company must coordinate its strategy across multiple specialized divisions. With the distinct examiners involved, the company faces a variety of examination styles within the Biotechnology & Pharmaceuticals area. This distribution requires managing different examiner relationships across the units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (38%) |
| §103 only | 2 (15%) |
| §112 only | 1 (8%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 3 (23%) |
| Multi-statute (no §101) | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 2 | 82.4% | +19.7% |
| KALLAL, ROBERT JAMES | 2 | 60.0% | +32.4% |
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| HIBSHMAN, SARAH GRACE | 1 | 38.9% | +40.0% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| SKIBINSKY, ANNA | 1 | 39.0% | +29.1% |
| BRACERO, ANDREW ANGEL | 1 | 92.3% | +20.0% |
| LUO, JAMMY NMN | 1 | — | — |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800129 | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | BRACERO, ANDREW ANGEL | 33d |
| 18928814 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | DAVIS, BRIAN J | — |
| 18708686 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | WILLIS, DOUGLAS M | — |
| 18702772 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596888 | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | KALLAL, ROBERT JAMES | 25d overdue |
| 17911376 | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | SKIBINSKY, ANNA | 21d |
| 18721283 | METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | HIBSHMAN, SARAH GRACE | — |
| 18164160 | LOCAL STEPS IN LATENT SPACE AND DESCRIPTORS-BASED MOLECULES FILTERING FOR CONDITIONAL MOLECULAR GENERATION | KALLAL, ROBERT JAMES | — |
| 17835167 | ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES | LUO, JAMMY NMN | — |
| 17479892 | METHYLATION DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A METHYLATION AGING CLOCK | VANNI, GEORGE STEVEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596888 | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | KALLAL, ROBERT JAMES | 25d overdue |
| 17911376 | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | SKIBINSKY, ANNA | 21d |
| 17800129 | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | BRACERO, ANDREW ANGEL | 33d |
| 18837846 | MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | ROBINSON, MIKHAIL O'DONNEL | — |
| 18837847 | MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18721283 | METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | HIBSHMAN, SARAH GRACE | — |
| 18708686 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | WILLIS, DOUGLAS M | — |
| 18704366 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| 2146 | 1 |
| 1635 | 1 |
| 2126 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18928814 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | DAVIS, BRIAN J | — | §112DP | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18837846 | MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | ROBINSON, MIKHAIL O'DONNEL | — | §103 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18837847 | MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | WHITE, DAWANNA SHAR-DAY | — | §103DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18721283 | METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | HIBSHMAN, SARAH GRACE | — | §102§103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18708686 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | WILLIS, DOUGLAS M | — | §112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18704366 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | O DELL, DAVID K | — | DP | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18702772 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | WILLIS, DOUGLAS M | — | §112DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18164160 | LOCAL STEPS IN LATENT SPACE AND DESCRIPTORS-BASED MOLECULES FILTERING FOR CONDITIONAL MOLECULAR GENERATION | KALLAL, ROBERT JAMES | 2146 | §101§103§112 | Non-Final OA | — | Pending | Feb 03, 2023 |
| 17911376 | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | SKIBINSKY, ANNA | 1635 | §101§103 | Final Rejection | 21d | Pending | Sep 13, 2022 |
| 17800129 | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | BRACERO, ANDREW ANGEL | 2126 | §103 | Non-Final OA | 33d | Pending | Aug 16, 2022 |
| 17835167 | ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES | LUO, JAMMY NMN | 1686 | §101§103 | Final Rejection | — | Pending | Jun 08, 2022 |
| 17596888 | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | KALLAL, ROBERT JAMES | 1685 | §101§112 | Non-Final OA | 25d overdue | Pending | Dec 20, 2021 |
| 17479892 | METHYLATION DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A METHYLATION AGING CLOCK | VANNI, GEORGE STEVEN | 1686 | §101§112DP | Non-Final OA | — | Pending | Sep 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial